Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan

Journal of Controlled Release

Volumn 153, Issue 3, 2011, Pages 288-296

  Riviere, Kareen ^a   Kieler Ferguson, Heidi M ^a   Jerger, Katherine ^a   Szoka Jr , Francis C ^a  

^a San Francisco   (United States)

Author keywords

C26 colon carcinoma; Chaotropic loading; Co encapsulation; Remote loading; Synergism

Indexed keywords

CHAOTROPIC LOADING; CO-ENCAPSULATION; COLON CARCINOMA; REMOTE LOADING; SYNERGISM;

AMMONIUM COMPOUNDS; LIPOSOMES; LOADING; MAMMALS; PHOSPHOLIPIDS; UREA;

TUMORS;

AMMONIUM DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; FLUOROOROTIC ACID; IRINOTECAN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; COLON CARCINOMA; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SOLUBILITY; ENCAPSULATION; IN VITRO STUDY; LIPOSOMAL DELIVERY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG COMBINATIONS; DRUG COMPOUNDING; DRUG SYNERGISM; HT29 CELLS; HUMANS; LIPOSOMES; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; OROTIC ACID; PARTICLE SIZE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960919311     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.05.005     Document Type: Article

References (38)

1. R.G. Azrak, S. Cao, H.K. Slocum, K. Toth, F.A. Durrani, M.B. Yin, L. Pendyala, W. Zhang, H.L. McLeod, Y.M. Rustum, Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts, Clin. Cancer Res. 10 (2004) 1121-1129. (Pubitemid 38198914)
2. J.L. Fischel, P. Rostagno, P. Formento, A. Dubreuil, M.C. Etienne, G. Milano, Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines, Br. J. Cancer 84 (2001) 579-585. (Pubitemid 32215889)
3. I. Grivicich, A. Regner, A.B. da Rocha, G.B. Kayser, D.P. Schunemann, L.B. Grass, P.A. Alves, J.A. Henriques, G. Schwartsmann, The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells, Chemotherapy 51 (2005) 93-102. (Pubitemid 40981065)
4. G.J. Peters, C.L. van der Wilt, C.J. van Moorsel, J.R. Kroep, A.M. Bergman, S.P. Ackland, Basis for effective combination cancer chemotherapy with antimetabolites, Pharmacol. Ther. 87 (2000) 227-253.
5. L.D. Mayer, T.O. Harasym, P.G. Tardi, N.L. Harasym, C.R. Shew, S.A. Johnstone, E.C. Ramsay, M.B. Bally, A.S. Janoff, Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice, Mol. Cancer Ther. 5 (2006) 1854-1863. (Pubitemid 44323254)
6. R.J. Tallarida, Drug synergism: its detection and applications, J. Pharmacol. Exp. Ther. 298 (2001) 865-872. (Pubitemid 32761897)
7. J. Vaage, D. Donovan, E. Mayhew, P. Uster, M. Woodle, Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes, Int. J. Cancer 54 (1993) 959-964. (Pubitemid 23267469)
8. S.A. Abraham, C. McKenzie, D. Masin, R. Ng, T.O. Harasym, L.D. Mayer, M.B. Bally, In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading, Clin. Cancer Res. 10 (2004) 728-738. (Pubitemid 38174011)
9. J. Wang, B. Goh, W. Lu, Q. Zhang, A. Chang, X.Y. Liu, T.M. Tan, H. Lee, In vitro cytotoxicity of stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells, Biol. Pharm. Bull. 28 (2005) 822-828. (Pubitemid 40740648)
10. Y. Yamashita, M.T. Krauze, T. Kawaguchi, C.O. Noble, D.C. Drummond, J.W. Park, K.S. Bankiewicz, Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts, Neuro Oncol. 9 (2007) 20-28. (Pubitemid 46543485)
11. M.T. Krauze, C.O. Noble, T. Kawaguchi, D. Drummond, D.B. Kirpotin, Y. Yamashita, E. Kullberg, J. Forsayeth, J.W. Park, K.S. Bankiewicz, Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts, Neuro Oncol. 9 (2007) 393-403.
12. J. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, R.J. Lee, Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil, J. Pharm. Pharm. Sci. 10 (2007) 350-357. (Pubitemid 350065179)
13. P. Tardi, S. Johnstone, N. Harasym, S. Xie, T. Harasym, N. Zisman, P. Harvie, D. Bermudes, L. Mayer, In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy, Leuk. Res. 33 (2009) 129-139.
14. P.G. Tardi, N. Dos Santos, T.O. Harasym, S.A. Johnstone, N. Zisman, A.W. Tsang, D.G. Bermudes, L.D. Mayer, Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo, Mol. Cancer Ther. 8 (2009) 2266-2275.
15. E.C. Ramsay, N. Dos Santos, W.H. Dragowska, J.J. Laskin, M.B. Bally, The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations, Curr. Drug Deliv. 2 (2005) 341-351. (Pubitemid 41277766)
16. L.D. Mayer, A.S. Janoff, Optimizing combination chemotherapy by controlling drug ratios, Mol. Interv. 7 (2007) 216-223. (Pubitemid 47437268)
17. W.F. Bayne, L.D. Mayer, C.E. Swenson, Pharmacokinetics of CPX-351 (cytarabine/ daunorubicin HCl) liposome injection in the mouse, J. Pharm. Sci. 98 (2009) 2540-2548.
18. T.O. Harasym, P.G. Tardi, N.L. Harasym, P. Harvie, S.A. Johnstone, L.D. Mayer, Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios, Oncol. Res. 16 (2007) 361-374. (Pubitemid 47413252)
19. G. Batist, K.A. Gelmon, K.N. Chi, W.H. Miller Jr., S.K. Chia, L.D. Mayer, C.E. Swenson, A.S. Janoff, A.C. Louie, Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors, Clin. Cancer Res. 15 (2009) 692-700.
20. D.C. Drummond, C.O. Noble, Z. Guo, K. Hong, J.W. Park, D.B. Kirpotin, Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy, Cancer Res. 66 (2006) 3271-3277.
21. A. Dicko, P. Tardi, X. Xie, L. Mayer, Role of copper gluconate/ triethanolamine in irinotecan encapsulation inside the liposomes, Int. J. Pharm. 337 (2007) 219-228. (Pubitemid 46756052)
22. P.G. Tardi, R.C. Gallagher, S. Johnstone, N. Harasym, M. Webb, M.B. Bally, L.D. Mayer, Coencapsulation of irinotecan and floxuridine into low cholesterolcontaining liposomes that coordinate drug release in vivo, Biochim. Biophys. Acta 1768 (2007) 678-687. (Pubitemid 46275599)
23. N. Kaiser, A. Kimpfler, U. Massing, A.M. Burger, H.H. Fiebig, M. Brandl, R. Schubert, 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties, Int. J. Pharm. 256 (2003) 123-131. (Pubitemid 36412145)
24. T.D. Heath, N.G. Lopez, W.H. Stern, D. Papahadjopoulos, 5-Fluoroorotate: a new liposome-dependent cytotoxic agent, FEBS Lett. 187 (1985) 73-75. (Pubitemid 15250020)
25. T.D. Heath, Methodology and experimental design for the study of liposomedependent drugs, Methods Enzymol. 391 (2005) 186-199. (Pubitemid 40254036)
26. T.D. Heath, N.G. Lopez, G.P. Lewis, W.H. Stern, Antiproliferative and anticontractile effects of liposome encapsulated fluoroorotate, Invest. Ophthalmol. Vis. Sci. 28 (1987) 1365-1372. (Pubitemid 17161244)
27. C. Heidelberger, L. Griesbach, B.J. Montag, D. Mooren, O. Cruz, R.J. Schnitzer, E. Grunberg, Studies on fluorinated pyrimidines. II. Effects on transplanted tumors, Cancer Res. 18 (1958) 305-317.
28. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, M.R. Boyd, New colorimetric cytotoxicity assay for anticancerdrug screening, J. Natl Cancer Inst. 82 (1990) 1107-1112. (Pubitemid 20213250)
29. T.C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv. Enzyme Regul. 22 (1984) 27-55.
30. T.C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol. Rev. 58 (2006) 621-681.
31. S. Clerc, Y. Barenholz, Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients, Biochim. Biophys. Acta 1240 (1995) 257-265. (Pubitemid 26004750)
32. V.H. Bono Jr., C.C. Cheng, E. Frei III, M.G. Kelly, Methyl-5- Fluoroorotate: synthesis and comparison with 5-fluoroorotic acid with respect to biological activity and cell entry, Cancer Res. 24 (1964) 513-517.
33. R.M. Straubinger, N.G. Lopez, R.J. Debs, K. Hong, D. Papahadjopoulos, Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes, Cancer Res. 48 (1988) 5237-5245.
34. S.A. Abraham, D.N. Waterhouse, L.D. Mayer, P.R. Cullis, T.D. Madden, M.B. Bally, The liposomal formulation of doxorubicin, Methods Enzymol. 391 (2005) 71-97. (Pubitemid 40254030)
35. D. Zucker, D. Marcus, Y. Barenholz, A. Goldblum, Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties, J. Control. Release 139 (2009) 73-80.
36. A. Dicko, A.A. Frazier, B.D. Liboiron, A. Hinderliter, J.F. Ellena, X. Xie, C. Cho, T. Weber, P.G. Tardi, D. Cabral-Lilly, D.S. Cafiso, L.D. Mayer, Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes, Pharm. Res. 25 (2008) 1702-1713.
37. E. Mayhew, Y.M. Rustum, F. Szoka, D. Papahadjopoulos, Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes, Cancer Treat. Rep. 63 (1979) 1923-1928. (Pubitemid 10138955)
38. M.E. Fox, S. Guillaudeu, J.M. Frechet, K. Jerger, N. Macaraeg, F.C. Szoka, Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates, Mol. Pharm. 6 (2009) 1562-1572.